Skip to main content
Biohit Oyj logo

Biohit Oyj — Investor Relations & Filings

Ticker · BIOBV ISIN · FI0009005482 LEI · 74370089ATTSNBXJVT29 HE Manufacturing
Open in API
Filings indexed 992 across all filing types
Latest filing 2022-02-09 Proxy Solicitation & In…
Country FI Finland
Listing HE BIOBV

About Biohit Oyj

https://www.biohithealthcare.com/en/

Biohit Oyj is a global biotechnology company that develops, manufactures, and markets innovative diagnostic products and services. The company specializes in tools for the early diagnosis and prevention of diseases, with a primary focus on gastroenterology. Its key offerings include the GastroPanel® blood test for assessing stomach health and screening for risks of gastric cancer, as well as diagnostic tests for conditions such as Helicobacter pylori infection. Operating under the mission "Innovating for Health," Biohit's products are designed to support medical research, facilitate early and accurate diagnosis, and improve patient quality of life.

Recent filings

Filing Released Lang Actions
Notice of Biohit Oyj's extraordinary general meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' issued by Biohit Oyj. It outlines the agenda, voting procedures, and instructions for shareholders to participate in the upcoming meeting. This type of document is a standard proxy solicitation and information statement provided to shareholders to facilitate their participation and voting in a corporate meeting.
2022-02-09 English
02086209.pdf
Management Reports Classification · 85% confidence The document is a stock exchange release from Biohit Oyj regarding the settlement of a legal dispute and a subsequent update to their financial guidance for 2021. While it contains financial figures, it is an announcement of a settlement and a guidance update rather than a full financial report. It does not fit into specific categories like 'Earnings Release' (which is usually a summary of results) or 'Legal Proceedings' (which is usually a report on litigation status). Given the nature of the announcement regarding financial guidance and settlement, it is best classified as a general regulatory filing.
2022-02-08 English
Biohit has settled the dispute concerning a breach of the patent license agreement and therefore specifies its financial guidance for 2021
Regulatory Filings Classification · 95% confidence The document is a stock exchange release from Biohit Oyj regarding the settlement of a legal dispute and a subsequent update to their financial guidance for 2021. While it contains financial figures, it is an announcement of guidance rather than a full financial report. It also discusses a legal settlement and a future extraordinary general meeting. Given the primary focus on updating financial guidance following a legal resolution, it fits best as a Regulatory Filing (RNS) as it is a general corporate announcement that does not fall into the specific categories of a full report or a dedicated legal proceeding document.
2022-02-08 English
02086198.pdf
Legal Proceedings Report Classification · 85% confidence The document is a stock exchange release (Pörssitiedote) from Biohit Oyj regarding the settlement of a patent license dispute and a subsequent update to their 2021 financial guidance. While it contains financial figures, it is an announcement of a settlement and a guidance update rather than a full financial report or a conference call transcript. Since it does not fit into specific categories like 'Earnings Release' (which usually refers to the full quarterly/annual results announcement) or 'Legal Proceedings' (which is for ongoing litigation updates), and it is a regulatory announcement regarding company performance and legal settlement, it is best classified as a general regulatory filing.
2022-02-08 Finnish
Biohit on sopinut patenttilisenssisopimuksen rikkomista koskevan erimielisyyden ja tarkentaa sen perusteella vuoden 2021 ennustettaan
Regulatory Filings Classification · 95% confidence The document is a stock exchange release (Pörssitiedote) from Biohit Oyj regarding the settlement of a patent license dispute and a subsequent update to their 2021 financial guidance. While it contains financial figures, it is an initial announcement of results and a material event (settlement), not the full financial report itself. Given the nature of the announcement regarding financial guidance and legal settlement, it falls under the category of general regulatory announcements.
2022-02-08 Finnish
01183218.pdf
Director's Dealing Classification · 100% confidence The document is titled 'Biohit Oyj Managers' Transactions' and details specific stock option acceptances by a senior manager (Suvi Elomaa). This falls under the category of Director's Dealing (DIRS), which covers reports of personal share or financial instrument transactions by company directors and executives.
2022-01-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.